Top Markets
Coin of the day
Human Metabolome Technologies, Inc. Human Metabolome Technologies, Inc.

Human Metabolome Technologies, Inc.

6090
Kedudukan dalam Saham #29370
Human Metabolome Technologies, Inc. is a biotechnology company based in... Human Metabolome Technologies, Inc. is a biotechnology company based in Tsuruoka, Japan, established in 2003. It focuses on developing and providing metabolomics technologies and solutions for a range of applications, including drug discovery, disease diagnosis, and food production primarily within Japan. The company offers a comprehensive suite of metabolome analysis services, encompassing global profiling, targeted assays, flux analysis, and lipidomics. Additionally, it develops biomarkers, such as Phosphorylethanolamine, which is measured in blood plasma as a marker for major depressive disorder. HMT's solutions address diverse areas like cancer metabolism, infectious diseases, basic and clinical research, food and nutrition, and microbiome studies. The company also fosters collaborations, notably with the Institute for Advanced Biosciences and Keio University, to further advance metabolome analysis technology.
Harga Saham
$3.86
Modal Pasaran
$21.49M
Perubahan (1 hari)
-0.17%
Perubahan (1 tahun)
-25.27%
Negara
JP
Perdagangan Human Metabolome Technologies, Inc. (6090)

Kategori

Pendapatan untuk Human Metabolome Technologies, Inc. (6090)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini Human Metabolome Technologies, Inc., pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Human Metabolome Technologies, Inc. dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
$5.27B -
US
$1.95B -
NL
$-3.09B -
US
$1.61B -
AU
- -
CH